skip to navigation skip to content
Search

Nektarios (Aris) Oraiopoulos

Fast Company: How open-source medicine could prepare us for the next pandemic

A study on drug repurposing co-authored by Dr Nektarios Oraiopoulos, University Lecturer in Operations Management at Cambridge Judge Business School, is quoted in the article. The study found that “about 31 per cent of drugs approved by the FDA had…

Read more

Pharma Voice: New pipeline pathways

Repurposing existing drugs could reduce cost and time when developing new medicine, but it’s not a straightforward approach. According to a study by Dr Nektarios Oraiopoulos, University Lecturer in Operations Management at Cambridge Judge, only two per cent of new…

Read more

Bias in diversity

Diversity on key corporate committees is supposed to produce better decisions. But a study at Cambridge Judge Business School finds that diverse views rarely 'average out' as assumed, but instead lead to systematic biases toward certain types of errors. Diversity…

Read more

2019 brainfood biasindiversity 883x432 1

Healthcare policy & drug development (The Cambridge Judge Business Debate podcast series)

How ageing societies can afford healthcare for all and reform an organisational system that has not kept pace with technology. L-R: Paul Tracey, Michael Kitson, Kamal Munir, Stefan Scholtes, Nektarios Oraiopoulos In this episode, joining podcast host Michael Kitson, University…

Read more

2019 debatepodcast healthcare featured 883x432 1

Pharmaceutical pipeline

Study on drug industry project selection by Dr Panos Markou, Professor Stelios Kavadias and Dr Nektarios Oraiopoulos of Cambridge Judge Business School wins Best Working Paper award at the annual meeting of the Institute for Operations Research and Management Science.…

Read more

2018 news pharmaceuticalpipeline 883x432 1

Manufacturing Chemist: Limits of drug repurposing

New research co-authored at Cambridge Judge Business School looks at drug repurposing and found that it’s not easy to find entirely new uses for existing molecules. The study is based on US Food and Drug Administration approvals and the full…

Read more

Limits of drug repurposing

Drug 'repurposing' has some high-profile wins, but a new study at Cambridge Judge Business School shows how hard it is to find entirely new uses for existing molecules. The “repurposing” of existing drugs can be valuable, but a new study…

Read more

Variety of medical drugs.

Inhibiting innovation

Dr Nektarios Oraiopoulos, University Lecturer in Operations Management at Cambridge Judge Business School, on how the organisational structures of large companies inhibit innovation, and what you can do to buck the trend. Innovation in practice requires experimentation. With experimentation comes the…

Read more

Inhibiting innovation.

A framework for drug development

'Science is not enough' for ensuring commercial success of new drugs, so a new journal article co-authored by Dr Nektarios (Aris) Oraiopoulos of Cambridge Judge outlines a framework to help pharma companies align better with end-customer priorities. In most industries,…

Read more

Drug development.

Phys.org: How to get teams to share information

Withholding key information within organisational silos might happen more often than we might like to admit. Now a new study suggests how and when companies should restore meaningful communication across the organisation. The study was co-authored by Cambridge Judge’s Dr…

Read more

Archives